These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35929392)

  • 21. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.
    Zhang J
    Inflamm Res; 2023 Sep; 72(9):1873-1876. PubMed ID: 37682322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
    Bateman RJ; Cummings J; Schobel S; Salloway S; Vellas B; Boada M; Black SE; Blennow K; Fontoura P; Klein G; Assunção SS; Smith J; Doody RS
    Alzheimers Res Ther; 2022 Nov; 14(1):178. PubMed ID: 36447240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.
    Hao W; Lenhart S; Petrella JR
    PLoS Comput Biol; 2022 Sep; 18(9):e1010481. PubMed ID: 36054214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
    Beveridge J; Kaniecki E; Naidu A; Silverglate BD; Grossberg G
    Expert Opin Emerg Drugs; 2024 Mar; 29(1):35-43. PubMed ID: 38193477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-amyloid Antibody Therapies for Alzheimer's Disease.
    Park KW
    Nucl Med Mol Imaging; 2024 Jun; 58(4):227-236. PubMed ID: 38932758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease.
    Lozupone M; Berardino G; Mollica A; Sardone R; Dibello V; Zupo R; Lampignano L; Castellana F; Bortone I; Stallone R; Daniele A; Altamura M; Bellomo A; Solfrizzi V; Panza F
    Expert Opin Investig Drugs; 2022 Aug; 31(8):759-771. PubMed ID: 35758153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.
    Kurkinen M
    Adv Clin Exp Med; 2023 Sep; 32(9):943-947. PubMed ID: 37676096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?
    Atwood CS; Perry G
    J Alzheimers Dis; 2023; 92(3):799-801. PubMed ID: 36847013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.
    Ceyzériat K; Zilli T; Millet P; Frisoni GB; Garibotto V; Tournier BB
    Curr Alzheimer Res; 2020; 17(2):112-125. PubMed ID: 32129164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets.
    Gu X; Qi L; Qi Q; Zhou J; Chen S; Wang L
    Biosci Trends; 2024 Mar; 18(1):49-65. PubMed ID: 38382942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives.
    Usman MB; Bhardwaj S; Roychoudhury S; Kumar D; Alexiou A; Kumar P; Ambasta RK; Prasher P; Shukla S; Upadhye V; Khan FA; Awasthi R; Shastri MD; Singh SK; Gupta G; Chellappan DK; Dua K; Jha SK; Ruokolainen J; Kesari KK; Ojha S; Jha NK
    J Prev Alzheimers Dis; 2021; 8(4):534-551. PubMed ID: 34585229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
    Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
    J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Passive Alzheimer's immunotherapy: A promising or uncertain option?
    Høilund-Carlsen PF; Revheim ME; Costa T; Alavi A; Kepp KP; Sensi SL; Perry G; Robakis NK; Barrio JR; Vissel B
    Ageing Res Rev; 2023 Sep; 90():101996. PubMed ID: 37414156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.
    Nicoll JAR; Buckland GR; Harrison CH; Page A; Harris S; Love S; Neal JW; Holmes C; Boche D
    Brain; 2019 Jul; 142(7):2113-2126. PubMed ID: 31157360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapy Developments in Alzheimer's Disease].
    Grimmer T
    Fortschr Neurol Psychiatr; 2022 Jul; 90(7-08):352-360. PubMed ID: 35588740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
    Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
    Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
    Høilund-Carlsen PF; Alavi A; Castellani RJ; Neve RL; Perry G; Revheim ME; Barrio JR
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.